PSMA-targeted therapy represents a promising therapeutic option for the treatment of advanced carcinomas and there are currently a number of PSMA-targeted therapeutic approaches being approved for clinical trials e.g., clear cell renal carcinoma, glioblastoma and hepatocellular carcinoma (ClinicalTrials.gov Identifier: NCT02607553, NCT02067156, NCT01777594, NCT01856933) [25]. The gene discussed is FOLH1; the disease is carcinoma.